Bisphenol-A plasma levels are related to inflammatory markers, visceral obesity and insulin-resistance: a cross-sectional study on adult male population

Journal of Translational Medicine

Rossella Valentino⁴  Pietro Formisano⁴  Francesco Beguinot⁴  Carmine Finelli²  Fabiana Ariemma⁵  Giuseppe Perruolo⁴  Domenico Liguoro⁴  Antonietta Liotti⁵  Serena Cabaro⁵  Federica Passaretti⁵  Vittoria D’Esposito⁵  Giovanni Tarantino¹  Silvia Savastano³ 

[1] INT “Fondazione Pascale”, Cancer Research Center of Mercogliano, Mercogliano, 83013, AV, Italy;Center of Obesity and Eating Disorders, Stella Maris Mediterraneum Foundation, C/da S. Lucia, Chiaromonte, Potenza, Italy;Department of Clinical Medicine and Surgery, “Federico II” University of Naples, via Pansini, 5, Naples, 80131, Italy;Institute of Experimental Endocrinology and Oncology (IEOS), National Council of Research (CNR), “Federico II” University of Naples, via Pansini, 5, Naples, 80131, Italy;Department of Translational Medical Sciences, “Federico II” University of Naples, via Pansini, 5, Naples, 80131, Italy

关键词: Metabolic Syndrome;    Visceral adiposity;    Obesity;    Bisphenol-A;    Endocrine-disruptors;   

Others  :  1212315
DOI  :  10.1186/s12967-015-0532-y

 received in 2015-03-09, accepted in 2015-05-12,  发布年份 2015

【 摘 要 】

Background

The current increase of obesity and metabolic syndrome (MS) focuses attention on bisphenol-A (BPA), “obesogen” endocrine disruptor, main plastic component. Aim was to verify the role of BPA in metabolic alterations, insulin resistance, low grade inflammation and visceral obesity.

Methods

A cross-sectional study was performed in 76 out of 139 environmentally exposed adult males, unselected Caucasian subjects, enrolled by routine health survey at the “Federico II” University of Naples outpatient facilities. BPA plasma levels (ELISA), metabolic risk factors, homeostasis model assessment of insulin resistance index, plasma monocyte chemoattractant protein 1, interleukin-6 (IL-6) and tumor necrosis factor-alpha were performed. Clinical and biochemical parameters have been compared with BPA and pro-inflammatory cytokines levels.

Results

In total 24 subjects out of 76 (32%) presented with waist circumference (WC) >102 cm, 36 (47%) had impaired fasting glucose and 24 (32%) subjects had insulin resistance [11 out 52 (21%) with WC ≤102 cm and 13 out of 24 with WC >102 cm (54%), χ² 6.825, p = 0.009]. BPA and pro-inflammatory cytokine levels were significantly higher in subjects with visceral adiposity (WC > 102 cm). BPA correlated with WC, triglycerides, glucose homeostasis and inflammatory markers. At the multivariate analysis WC and IL-6 remained the main predictors of BPA.

Conclusions

Detectable BPA plasma levels have been found also in our population. The strictly association between BPA and WC, components of MS, and inflammatory markers, further supports the BPA role in visceral obesity-related low grade chronic inflammation.

【 授权许可】

   
2015 Savastano et al.

【 图 表 】

Figure1.

Figure2.

【 参考文献 】

• [1]Lubrano C, Genovesi G, Specchia P, Costantini D, Mariani S, Petrangeli E et al.. Obesity and metabolic comorbidities: environmental diseases? Oxid Med Cell Longev. 2013; 2013:640673.
• [2]LaKind JS, Goodman M, Naiman DQ. Use of NHANES data to link chemical exposures to chronic diseases: a cautionary tale. PLoS One. 2012; 7:e51086.
• [3]Rubin BS. Bisphenol A: an endocrine disruptor with widespread exposure and multiple effects. J Steroid Biochem Mol Biol. 2011; 127:27-34.
• [4]Vom Saal FS, Nagel SC, Coe BL, Angle BM, Taylor JA. The estrogenic endocrine disrupting chemical bisphenol A (BPA) and obesity. Mol Cell Endocrinol. 2012; 354:74-84.
• [5]Xiaoqian G, Hong-Sheng W. Impact of bisphenol A on the cardiovascular system - epidemiological and experimental evidence and molecular mechanisms. Int J Environ Res Public Health. 2014; 11:8399-8413.
• [6]Müllerová D, Kopecky J. White adipose tissue: storage and effector site for environmental pollutants. Physiol Res. 2007; 56:375-381.
• [7]Welshons WV, Nagel SC, vom Saal FS. Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure. Endocrinology. 2006; 147:S56-S69.
• [8]Vandenberg LN, Hauser R, Marcus M, Olea N, Welshons WV. Human exposure to bisphenol A (BPA). Reprod Toxicol. 2007; 24:139-177.
• [9]Rochester JR. Bisphenol A and human health: a review of the literature. Reprod Toxicol. 2013; 42:132-155.
• [10]Rezg R, El-Fazaa S, Gharbi N, Mornagui B. Bisphenol A and human chronic diseases: current evidences, possible mechanisms, and future perspectives. Environ Int. 2014; 64:83-90.
• [11]Shankar A, Teppala S. Relationship between urinary bisphenol A levels and diabetes mellitus. J Clin Endocrinol Metab. 2011; 96:3822-3826.
• [12]Teppala S, Madhavan S, Shankar A. Bisphenol A and metabolic syndrome: results from NHANES. Int J Endocrinol. 2012; 2012:598180.
• [13]Carwile JL, Michels KB. Urinary bisphenol A and obesity: NHANES 2003–2006. Environ Res. 2011; 111:825-830.
• [14]Silver MK, O’Neill MS, Sowers MR, Park SK. Urinary bisphenol A and type-2 diabetes in U.S. adults: data from NHANES 2003–2008. PLoS One. 2011; 6:e26868.
• [15]Wang T, Li M, Chen B, Xu M, Xu Y, Huang Y et al.. Urinary bisphenol A (BPA) concentration associates with obesity and insulin resistance. J Clin Endocrinol Metab. 2012; 97:E223-E227.
• [16]Vandenberg LN, Chahoud I, Padmanabhan V, Paumgartten FJ, Schoenfelder G. Biomonitoring studies should be used by regulatory agencies to assess human exposure levels and safety of bisphenol A. Environ Health Perspect. 2010; 118:1051-1054.
• [17]Vandenberg LN, Ehrlich S, Belcher SM, Ben-Jonathan N, Dolinoy DC, Hugo ER et al.. Low dose effects of bisphenol A. An integrated review of in vitro, laboratory animal, and epidemiology studies. Endocr Disrupt. 2013; 1(1):e25078.
• [18]Takeuchi T, Tsutsumi O, Ikezuki Y, Kamei Y, Osuga Y, Fujiwara T et al.. Elevated serum bisphenol A levels under hyperandrogenic conditions may be caused by decreased UDP-glucuronosyltransferase activity. Endocr J. 2006; 54:485-491.
• [19]Kinch CD, Ibhazehiebo K, Jeong JH, Habibi HR, Kurrasch DM. Low-dose exposure to bisphenol A and replacement bisphenol S induces precocious hypothalamic neurogenesis in embryonic zebrafish. Proc Natl Acad Sci USA. 2015; 112:1475-1480.
• [20]Liu J, Yu P, Qian W, Li Y, Zhao J, Huan F et al.. Perinatal bisphenol A exposure and adult glucose homeostasis: identifying critical windows of exposure. PLoS One. 2013; 8(5):e64143.
• [21]Alonso-Magdalena P, Vieira E, Soriano S, Menes L, Burks D, Quesada I et al.. Bisphenol A exposure during pregnancy disrupts glucose homeostasis in mothers and adult male offspring. Environ Health Perspect. 2010; 118:1243-1250.
• [22]Mielke H, Gundert-Remy U. Bisphenol A levels in blood depend on age and exposure. Toxicol Lett. 2009; 190:32-40.
• [23]Ohkuma H, Abe K, Ito M, Kokado A, Kambegawa A, Maeda M. Development of a highly sensitive enzyme-linked immunosorbent assay for bisphenol A in serum. Analyst. 2002; 127:93-97.
• [24]Dekant W, Völkel W. Human exposure to bisphenol A by biomonitoring: methods, results and assessment of environmental exposures. Toxicol Appl Pharmacol. 2008; 228:114-134.
• [25]Völkel W, Colnot T, Csanády GA, Filser JG, Dekant W. Metabolism and kinetics of bisphenol a in humans at low doses following oral administration. Chem Res Toxicol. 2002; 15:1281-1287.
• [26]Rodríguez-Ramírez G, Reyes-Romero MA. Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol. 2013; 2013:678159.
• [27]Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G et al.. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998; 47:1643-1649.
• [28]Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB et al.. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000; 23:57-63.
• [29]Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al.. American Heart Association; National Heart, Lung, and Blood Institute; Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112:2735-2752.
• [30]Rousseeuw PJ, Leroy AM (1987) Robust regression and outlier detection. Wiley-Interscience, John Wiley and Sons, New York. ISBN 0-471-85233-3
• [31]Valentino R, D’Esposito V, Passaretti F, Liotti A, Cabaro S, Longo M et al.. Bisphenol-A impairs insulin action and up-regulates inflammatory pathways in human subcutaneous adipocytes and 3T3-L1 cells. PLoS One. 2013; 8:e82099.
• [32]Tarantino G, Valentino R, Di Somma C, D’Esposito V, Passaretti F, Pizza G et al.. Bisphenol A in polycystic ovary syndrome and its association with liver-spleen axis. Clin Endocrinol (Oxf). 2013; 78:447-453.